Sanodyne Therapeutics

Nocion Therapeutics, originally founded as Sanodyne Therapeutics, is a clinical-stage biotechnology company developing a novel class of nociceptor-selective treatments for conditions involving sensory neuron activation. The company's platform is based on the discovery that permanently charged sodium channel blockers can be selectively delivered into activated pain- and itch-sensing neurons through large-pore ion channels like TRPV1. This targeted approach aims to provide potent relief for symptoms such as chronic cough, itch, and pain without the side effects associated with systemic drugs or traditional local anesthetics. Nocion's lead candidate, NTX-1175, is a first-in-class small molecule currently in Phase 2 clinical development for chronic cough. The company was founded by renowned scientists from Harvard Medical School and Boston Children's Hospital and is supported by a syndicate of top-tier life science venture capital firms.